TrialJCO global oncology2021

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.

Khalid AlSaleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.